NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT
technology, today announced results from a pre-clinical study showing that Vitaros
, the Company’s NexACT-based alprostadil product, significantly promoted healing of deep tissue wounds. Specifically, in a pig model, subjects with deep tissue wounds that were administered 200 mcgs of Vitaros healed four times faster than those receiving placebo over a 21-day period. This deep-seeded, wound healing pig model is widely regarded as the gold standard for pre-clinical testing of efficacy of wound-healing treatments. Vitaros is currently in late-stage development for the treatment of erectile dysfunction.
Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, “Poor blood supply is often a major factor in patients with healing failure. Alprostadil is a well known vasodilator which can enhance local microcirculation by inducing capillary dilation and neovascularization. The aim of our study was to test the safety and efficacy of Vitaros and its potential to promote wound healing in a long-term pre-clinical model. These initial results were very encouraging and warrant further testing of our NexACT-based alprostadil product in human clinical trials.”
NexMed also announced today that management will hold a conference call to discuss 2010 first quarter financial results and ongoing corporate activities, on Friday, May 14, 2010 at 12:00 p.m. EDT. The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of the U.S. by dialing (201) 689-8031 and asking the conference operator for the NexMed Conference Call. The teleconference replay will be available for one week by dialing (877) 660-6853 within the U.S., and outside of the U.S. by dialing (201) 612-7415. Replay pass codes 286 and 350779 are both required for playback. The conference call will also be available live, via Webcast, at:
. The Webcast replay will be available for three months following the event.
NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for
pharmacology services and research models. The Company’s goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT
drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT
-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites:
Forward-Looking Statement Safe Harbor for NexMed
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company including but not limited to its ability to replicate pre-clinical results in human clinical trials.